Nat Comm: 抑制肠道中树突状细胞的CD40通路治疗肠炎

2017-03-16 Leo.c MedSci原创

CD40通路的激活破坏了CD103+树突状细胞促使抑制炎症的Treg细胞的产生。针对CD40通路进行干预可以促使Treg细胞产生,从而抑制过激的肠道免疫反应及肠炎。

人的肠道系统存在数以万计的共生菌。为了不使这些共生菌引起过强的免疫反应,在肠道中有大量的Treg 细胞来维持共生菌和免疫系统的平衡。肠道中的巨噬细胞(macrophages)以及树突状细胞(dendritic cells)起到识别共生菌然后在引流淋巴结(draining lymph node)中帮助产生大量的Treg 细胞来抑制免疫系统对这些共生菌的免疫反应。然而,肠道中的树突状细胞同时也产生促炎因子包括IL-17A和IFN-γ。机体是如何平衡肠道中的树突状细胞进行抑制或促进免疫反应的功能?

在本期的Nature Communication杂志中,Christian Barthels 及其同事证明了CD40/CD40L信号通路的激活对肠道中的树突状细胞的功能起到重要作用。本文的作者们通过使用基因编辑后的老鼠,使实验鼠的树突状细胞持续激活CD40通路,发现肠道中的CD103+树突状细胞从肠道黏膜(lamina propia)移动到肠系膜淋巴结(mesenteric lymph node),从而在肠道黏膜有减少数量的树突状细胞以及Treg 细胞。也因此导致了肠道中的促炎的Th1/Th17细胞的免疫反应增强导致肠道细菌紊乱以及严重的肠炎。

这项研究揭示,CD40通路的激活破坏了CD103+树突状细胞促使抑制炎症的Treg细胞的产生。针对CD40通路进行干预可以促使Treg细胞产生,从而抑制过激的肠道免疫反应及肠炎。


原始出处:

Christian Barthels, Ana Ogrinc, Verena Steyer, et al., CD40-signalling abrogates induction of RORγt+ Treg cells by intestinal CD103+ DCs and causes fatal colitis. Nature Communications 8, Article number: 14715 (2017) doi:10.1038/ncomms14715

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1864216, encodeId=ae2f18642164a, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Wed Jan 31 14:16:00 CST 2018, time=2018-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881753, encodeId=88bf1881e53ed, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Apr 14 18:16:00 CST 2017, time=2017-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=181413, encodeId=fcf01814135f, content=感谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28761705280, createdName=cuiyejia, createdTime=Mon Mar 20 10:30:47 CST 2017, time=2017-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=180888, encodeId=075818088833, content=谢谢分享,好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28761705280, createdName=cuiyejia, createdTime=Sat Mar 18 12:44:16 CST 2017, time=2017-03-18, status=1, ipAttribution=)]
    2018-01-31 qidongfanjian
  2. [GetPortalCommentsPageByObjectIdResponse(id=1864216, encodeId=ae2f18642164a, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Wed Jan 31 14:16:00 CST 2018, time=2018-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881753, encodeId=88bf1881e53ed, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Apr 14 18:16:00 CST 2017, time=2017-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=181413, encodeId=fcf01814135f, content=感谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28761705280, createdName=cuiyejia, createdTime=Mon Mar 20 10:30:47 CST 2017, time=2017-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=180888, encodeId=075818088833, content=谢谢分享,好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28761705280, createdName=cuiyejia, createdTime=Sat Mar 18 12:44:16 CST 2017, time=2017-03-18, status=1, ipAttribution=)]
    2017-04-14 liye789132251
  3. [GetPortalCommentsPageByObjectIdResponse(id=1864216, encodeId=ae2f18642164a, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Wed Jan 31 14:16:00 CST 2018, time=2018-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881753, encodeId=88bf1881e53ed, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Apr 14 18:16:00 CST 2017, time=2017-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=181413, encodeId=fcf01814135f, content=感谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28761705280, createdName=cuiyejia, createdTime=Mon Mar 20 10:30:47 CST 2017, time=2017-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=180888, encodeId=075818088833, content=谢谢分享,好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28761705280, createdName=cuiyejia, createdTime=Sat Mar 18 12:44:16 CST 2017, time=2017-03-18, status=1, ipAttribution=)]
    2017-03-20 cuiyejia

    感谢分享,学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1864216, encodeId=ae2f18642164a, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Wed Jan 31 14:16:00 CST 2018, time=2018-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1881753, encodeId=88bf1881e53ed, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Apr 14 18:16:00 CST 2017, time=2017-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=181413, encodeId=fcf01814135f, content=感谢分享,学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28761705280, createdName=cuiyejia, createdTime=Mon Mar 20 10:30:47 CST 2017, time=2017-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=180888, encodeId=075818088833, content=谢谢分享,好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=28761705280, createdName=cuiyejia, createdTime=Sat Mar 18 12:44:16 CST 2017, time=2017-03-18, status=1, ipAttribution=)]
    2017-03-18 cuiyejia

    谢谢分享,好好学习

    0

相关资讯

J immunol:肠道上皮细胞损伤引发肠炎的分子机制

肠道上皮细胞是保护人体的一道重要的屏障。上皮细胞的损伤及后续引发的屏障功能的损坏都会最终导致炎症反应的发生,包括IBD等等。因此,上皮细胞的自我损伤修复对于重建肠道屏障以及组织的稳态调节具有重要的意义。粘膜伤口的愈合依赖于上皮细胞的增殖以及迁移。与免疫细胞以及成纤维细胞不同,上皮细胞的迁移是聚

腹泻就诊身亡,医院被判赔35万

北京晨报9月17日消息,72岁的糖尿病患者叶某因腹泻到医院就诊,被诊断为“肠炎”。然而次日症状加重,送医一周后死亡。医院确定死亡原因为糖尿病高渗昏迷。由于认为医院诊治不当导致患者死亡,叶某的老伴和两个儿子将北京和平里医院和北京安贞医院告上法庭。一审判决北京和平里医院赔偿35万余元后,该院提出上诉。但北京市二中院终审维持原判。叶某家属起诉称,叶某患有糖尿病20年。2013年10月1日,他因腹泻至和平

Nat Immunol:itch抑制IL-17介导的肠炎机制

炎症反应是宿主抵抗微生物侵染以及组织损伤的保护性反应。然而,失去控制的炎症反应容易提高癌症病发与生长的风险。例如,患有IBD以及溃疡性肠炎的患者更加容易患大肠癌。因此,了解大肠炎症反应的机制对于理解大肠癌的发病原因十分重要。越来越多的证据表明IL-17在肠道炎症反应以及肿瘤生成中具有关键的作用,而IL-17在肠道中的特异性表达主要由Th17细胞、γδT细胞以及天然淋巴细胞完成。IL-17能够通过引

Science:肠炎药物vedolizumab或可治疗艾滋病

导语:近日,来自美国埃默里大学的科学家们发现,一种针对肠道炎症的药物可以治疗艾滋病。这项不同寻常但令人激动的研究发表在了《科学》杂志上,它有望为艾滋病患者带来全新的治疗手段。近日,来自美国埃默里大学的科学家们发现,一种针对肠道炎症的药物可以治疗艾滋病。这项不同寻常但令人激动的研究发表在了《科学》杂志上,它有望为艾滋病患者带来全新的治疗手段。艾滋病,全称是获得性免疫缺陷综合征,是一种危害性极大的传染

Lancet:痛痛痛!罕见原因导致腹痛-案例报道

患者女,14岁,腹痛2天就诊,伴非胆汁性呕吐。查体:脸色苍白,弥漫性腹部压痛,肠鸣音减弱。辅助检查:血红蛋白 88 g/L,白细胞总数 3.6 × 109/L,血小板 96 × 109/L,红细胞沉降率(ESR) 54 mm/h;尿常规正、血和尿培养未见明显异常;其他血液检查、胸部平片、腹部B超、大便培养、显微镜和内镜检查无异常。腹部平片显示小肠大肠扩张,但没有肠梗阻或气腹。经验性静脉输注环丙沙星

Nat Med:CARD9通过调节肠道微生物代谢产物影响肠炎恢复能力

肠道微生物对于宿主的营养以及健康都具有重要的作用。这脆弱的生态平衡的打破会引起多种疾病,其中包括炎症性肠炎(IBD),CARD9是引发IBD的多种重要基因之一,它负责介导由模式识别受体激活后产生的胞内信号,包括NOD2,C type Lectin MAPK以及TLR信号通路等等。 CARD9能够通过IL-22调节肠炎的疾病调控,此前研究显示,CARD9缺失突变性小鼠更容易因肠道真菌感染引发肠炎